article thumbnail

LIVE 2025 Day One: Backlogs and Healthcare and AI, Oh My!

IP Watchdog

IPWatchdog LIVE opened today with a sneak preview of the latest episode of the IPWatchdog Unleashed podcast, which will be published Monday, and where IPWatchdog Founder and CEO Gene Quinn will examine the current state of the U.S.

article thumbnail

Foreign Price Controls: A Risk to U.S. Medical Innovation and Patient Access

IP Watchdog

As policymakers consider the future of American healthcare, it is imperative to recognize the potential dangers of adopting foreign price controls for life-saving medications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI in Pharmaceuticals: From Discovery to Market

Complex Discovery

Editor’s Note: Artificial intelligence (AI) is transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, streamline clinical trials, and fortify intellectual property (IP) strategies.

article thumbnail

Brazilian Congress Debates Regulatory Data Protection for Pharmaceutical Products

IP Watchdog

In May 2024, the Brazilian Senate Committee on Science, Technology, Innovation, and Informatics hosted two public hearings to discuss implementing Regulatory Data Protection (RDP) for pharmaceutical products of human use. The call for hearings (REQ 27/2023) was presented by Senator Izalci Lucas (Liberal Party).

article thumbnail

Dissent Today, Majority Tomorrow—A Federal Circuit Approach to Rehearing

IP Watchdog

recently in Novartis Pharmaceuticals Corp. Accord Healthcare Inc. But in Novartis Pharmaceuticals v. Accord Healthcare, neither of the panel members in the majority of the original opinion even agreed to rehear the case, let alone agreed to reverse their prior ruling. Talk about snatching victory from the jaws of defeat!

article thumbnail

CAFC Affirms ITC’s Invalidation of Sweetener Patent Under On-Sale Bar, Citing Helsinn

IP Watchdog

Supreme Court’s reasoning in Helsinn Healthcare v. Teva Pharmaceuticals (2019), the Federal Circuit rejected Celanese’s contentions that statutory changes wrought by the America Invents Act (AIA) altered the on-sale bar such that sales of products manufactured by an undisclosed process would not invalidate patents claiming that process.

article thumbnail

The Pharmacist Lawyer: Bridging the Gap for Better Healthcare – Thorrun Govind – S7E11

Legally Speaking

Thorrun’s unique journey highlights the intriguing intersection of healthcare and legal expertise, demonstrating that the boundaries of traditional career paths can be fluid and dynamic. Her experience in healthcare advisory law particularly in the area of inquests. Join us now on your favourite podcast streaming app!